Polycyclic guanine derivative phosphodiesterase V inhibitors

Abstract

A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:

1 - 19 . (canceled)  
     
     
         20 . A pharmaceutical composition comprising a compound selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a salt or solvate thereof, and a pharmaceutically acceptable carrier.  
     
     
         21 - 23 . (canceled)  
     
     
         24 . A method for treating a physiological disorder, symptom or disease in a patient in need of such treatment, comprising administering to the patient an effective amount of the composition of  claim 20 , wherein the physiological disorder, symptom or disease is selected from the group consisting of urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, post-angioplasty restenosis, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic condition associated with atony, pulmonary hypertension, ischemic heart, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular, renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia and cancer.  
     
     
         25 . The method according to  claim 24 , wherein the physiological disorder, symptom or disease is a urogenital disorder, symptom or disease.  
     
     
         26 . The method according to  claim 25 , wherein the urogenital disorder is erectile dysfunction.  
     
     
         27 . The method according to  claim 25 , wherein the urogenital disorder is impotence.  
     
     
         28 . A method for elevating a cGMP level in a patient, comprising administering to the patient an effective amount of the composition of  claim 20 .  
     
     
         29 - 31 . (canceled)  
     
     
         32 . The method of  claim 24  wherein the composition is administered to a patient in an amount ranging from about 1 to about 1000 milligrams of the compound per day.  
     
     
         33 . A pharmaceutical composition comprising a compound selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a salt or solvate thereof, and a pharmaceutically acceptable carrier.  
     
     
         34 . A method for treating a physiological disorder, symptom or disease in a patient in need of such treatment, comprising administering to the patient an effective amount of the composition of  claim 33 , wherein the physiological disorder, symptom or disease is selected from the group consisting of urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, post-angioplasty restenosis, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic condition associated with atony, pulmonary hypertension, ischemic heart, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular, renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia and cancer.  
     
     
         35 . The method according to  claim 34 , wherein the physiological disorder, symptom or disease is a urogenital disorder, symptom or disease.  
     
     
         36 . The method according to  claim 35 , wherein the urogenital disorder is erectile dysfunction.  
     
     
         37 . The method according to  claim 35 , wherein the urogenital disorder is impotence.  
     
     
         38 . A method for elevating a cGMP level in a patient, comprising administering to the patient an effective amount of the composition of  claim 33 .  
     
     
         39 . The method of  claim 34  wherein the composition is administered to a patient in an amount ranging from about 1 to about 1000 milligrams of the compound per day.  
     
     
         40 . A pharmaceutical composition comprising a compound selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a salt or solvate thereof, and a pharmaceutically acceptable carrier.  
     
     
         41 . A method for treating a physiological disorder, symptom or disease in a patient in need of such treatment, comprising administering to the patient an effective amount of the composition of  claim 40 , wherein the physiological disorder, symptom or disease is selected from the group consisting of urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, post-angioplasty restenosis, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic condition associated with atony, pulmonary hypertension, ischemic heart, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular, renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia and cancer.  
     
     
         42 . The method according to  claim 41 , wherein the physiological disorder, symptom or disease is a urogenital disorder, symptom or disease.  
     
     
         43 . The method according to  claim 42 , wherein the urogenital disorder is erectile dysfunction.  
     
     
         44 . The method according to  claim 42 , wherein the urogenital disorder is impotence.  
     
     
         45 . A method for elevating a cGMP level in a patient, comprising administering to the patient an effective amount of the composition of  claim 41 .  
     
     
         46 . The method of  claim 42  wherein the composition is administered to a patient in an amount ranging from about 1 to about 1000 milligrams of the compound per day.